Jan 23 (Reuters) - Vitrolife AB VITR.ST :
* VITROLIFE GROUP MAKES AN IMPAIRMENT CHARGE OF SEK 4.3
BILLION
RELATING TO IGENOMIX AND PROVIDES PRELIMINARY FINANCIALS FOR THE
FOURTH QUARTER 2023
* VITROLIFE - PRELIMINARY FIGURES FOR Q4, WITH SALES OF SEK
904
MILLION, CORRESPONDING TO 6% GROWTH IN SEK, GROSS MARGIN OF
56.9% AND EBITDA MARGIN OF 32.5%.
* VITROLIFE - IMPAIRMENT REPRESENTS 31% OF TOTAL AMOUNT OF
ACCOUNTED GOODWILL AND OTHER INTANGIBLE ASSETS ATTRIBUTED TO
ACQUISITION OF IGENOMIX
* VITROLIFE - IMPAIRMENT PARTLY DUE TO INFLATED GOODWILL, BY
APPRECIATION OF SHARE PRICE BETWEEN SIGNING AND ISSUANCE OF NEW
SHARES DURING TRANSACTION
Source text for Eikon: ID:nWkr2jpNyl
Further company coverage: VITR.ST
((Reuters.Briefs@thomsonreuters.com;))